




Precision Psychedelic Therapy

Investor presentation – May 2024

ASX : TYP

This presentation has been authorized for release by the Board of Tryptamine Therapeutics Limited



DISCLAIMERS

The information contained in this presentation (the "Presentation") has been prepared by Trypt Therapeutics Inc. ("Trypt" or the "Company") and contains information pertaining to the business, operations and assets of the Company. The information contained in this Presentation (a) is provided as at the date hereof and is subject to change without notice, (b) is for informational purposes only and does not purport to contain all information (including all material information) that may be necessary or desirable to fully and accurately evaluate the Company, (c) did not take into account the investment objectives, financial situation and particular needs of any particular investor, (d) is not to be considered as a recommendation by the Company that any person make an investment in Trypt, and (e) further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the Presentation. Those acting upon any information without advice do so entirely at their own risk.

This Presentation does not constitute an offer to sell or solicitation of an offer to buy any of the securities of Trypt. The sole purpose of this Presentation, in paper or electronic form, is strictly for information purposes. Neither Trypt, nor any of its current or proposed directors, officers, owners, managers, partners, consultants, employees, affiliates or representatives, make any warranty or representation, whether express or implied, or assume any legal liability or responsibility for any action taken in reliance upon this Presentation, or for the accuracy, completeness, fairness, or usefulness of any information disclosed in this Presentation.

Forward Looking Information. This Presentation contains forward looking statements with respect to Trypt. By their nature, forward looking statements involve risks and uncertainties and are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. In addition, the forward-looking statements require Trypt to make assumptions and are subject to inherent risks and uncertainties. There is significant risk that the forward-looking statements will not prove to be accurate, that Trypt's assumptions may not be correct and that actual results may differ materially from such forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements. Generally, forward looking statements can be identified by the use of terminology such as "anticipate", "will", "expect", "may", "continue", "could", "estimate", "forecast", "plan", "potential" and similar expressions. Forward looking statements contained in this Presentation may include, but are not limited to statements with respect to the outlook for the psilocybin industry and related industries; challenges and opportunities related to the psilocybin industry; the completion and timing of clinical studies; the ability of any patents resulting from Trypt's patent applications to protect the commercial prospects of its assets; the achievement, and the timing of, certain development milestones and the successful execution of Trypt's business strategy (including its business model and mission); the use and benefits of Trypt's products and services; demographic and market size/trends; forecasts of revenue and financial projections/growth potential; Trypt's ability to obtain marketing exclusivity for any of its approved drug products; anticipated capitalization, projected milestones and the go-forward management of Trypt; These forward looking statements are based on a number of assumptions which may prove to be incorrect including, but not limited to: general economic, market and business conditions, the outcome of research studies, the ability to obtain certain approvals, the accuracy of cost estimates, ability to obtain sufficient capital on satisfactory terms, availability of equipment and supplies, changes in customer demand, the successful and timely implementation of capital projects, currency exchange rates and the impact of changes in applicable laws and regulations. The forward-looking statements contained in this Presentation are made as of the date hereof or the dates specifically referenced in this Presentation, where applicable. Except as required by law, Trypt undertakes no obligation to update publicly or to revise any forward-looking statements that are contained or incorporated in this Presentation. All forward looking statements contained in this Presentation are expressly qualified by this cautionary statement.

Third-Party Information. This Presentation includes market and industry data obtained from various publicly available sources and other sources believed by the Company to be reliable. Although the Company believes it to be reliable, the Company has not independently verified any of the data from third-party sources referred to in this Presentation or analyzed or verified the underlying reports relied upon or referred to by such sources, or ascertained the underlying assumptions relied upon by such sources. The Company does not make any representation or warranty, express or implied as to the accuracy of such information. No responsibility or liability is accepted for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this Presentation. Some numbers in this Presentation may not be exact or add consistently due to rounding.

Accordingly, neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this Presentation or any document supplied with this Presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed.

Electronic Form. This Presentation may have been sent to you in an electronic form. You are reminded that documents transmitted via this medium may be altered or changed during the process of electronic transmission. You are responsible for protecting against viruses and other destructive items. Your receipt of this electronic transmission is at your own risk, and it is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature. As a consequence of the above, neither the Company nor any director, officer, employee or agent of any of them or any affiliate of any such person accepts any liability or responsibility whatsoever in respect of any difference between the document distributed to you in electronic format and the hard copy version that may be made available to you.

This Presentation and its contents are confidential and should not be distributed, published or reproduced in whole or in part or disclosed by recipients to any other person without the prior written consent of the Company. The Company does not assume responsibility for liabilities, losses or damages suffered by the recipients of this Presentation or any other person as a result of the circulation, reproduction or use of this Presentation.

Psilocybin. Psilocybin is currently a Schedule III drug under the Controlled Drugs and Substances Act, S.C. 1996, c. 19 (the "CDSA") and it is a criminal offence to possess substances under the CDSA without a prescription. Health Canada has not approved psilocybin as a drug. While the Company is focused on developing products using psilocybin, the Company does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances. The Company does not currently manufacture, store or otherwise handle psilocybin directly and will only do so through agents within laboratory and clinical trial settings conducted within approved regulatory frameworks. The Company's products that contain psilocybin or other psychedelic compounds will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed.

All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding.

Adverse effects of psilocybin and its derivatives can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimens used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

A Precision Approach to Psychedelic Medicine

With a focus on solving:

EATING DISORDERS & CHRONIC PAIN



Investment Highlights

Pioneering a precision approach to psychedelics, targeting precise drug blood levels in patients

Transformative and commercially scalable intellectual property (IV-Infused Psilocin)

- Addresses the critical limitations of oral dosing of psilocybin
- Platform has broad applicability and out-licensing potential
- Multiple near term value creating catalysts

Positioned to take advantage of recent positive changes to TGA regulations in Australia

First mover advantage and IP protection for indications targeted

Clinical trials ongoing

- Positive efficacy data previously announced for Binge Eating Disorder (80% reduction in binge eating episodes)
- Two additional INDs cleared to proceed with Phase 2 clinical trials (fibromyalgia and IBS)
- Preparations for first clinical trials in Australia for IV-infused Psilocin being finalised

Partnered with multiple leading academic institutions for Phase 2 trials

- Harvard University/Mass General Hospital (IBS)
- University of Michigan (Fibromyalgia)
- University of Florida (Binge Eating Disorder)

Experienced management team with proven biotech and drug approval success


World-class scientific advisory board chaired by renowned expert, Robin Carhart-Harris



Corporate overview

Snapshot:	
ASX code:	TYP
Shares on issue:	1.089Bn
Market capitalisation: (at \$0.02 per share)	~\$22.7m
Cash at bank: (as at 29 May 2024)	~\$6.7m
Debt:	Nil

Board of Directors	
Non-Executive Chairman	Mr Mark Davies
Chief Executive Officer	Mr Jason Carroll
Chief Business Officer	Mr Peter Molloy
Non-Executive Director	Mr Chris Ntoumenopoulos
Non-Executive Director	Mr Clarke Barlow
Non-Executive Director	Mr Gage Jull



Major shareholders	
Dr William James Garner	17.47%
Mr Jason Carroll	2.63%
Mr Herwig Janssen	2.20%
Mr Ludwig Criel	2.20%
Grayhawk Capital Pty Ltd	1.27%
Top 20:	46.56%

World class team with proven Leadership



JASON CARROLL
Chief Executive Officer

A seasoned and successful leader with over 30 years experience in healthcare sector



JIM GILLIGAN, PH.D.
Chief Scientific Officer

Over 35 years experience in Biopharmaceutical industry



JIM O'NEILL
Chief Financial Officer

Over 30 years as a finance executive with public and private multi-national businesses



PETER MOLLOY
Chief Business Officer

Over 25 years as an entrepreneur, advisor and institutional investor in the healthcare sector



MICHAEL SILVERMAN, M.D.
Chief Medical Officer

Over 30 years experience of clinical development in biotech sector

SCIENTIFIC ADVISORY BOARD



ROBIN CARHART-HARRIS
PH.D., (CHAIR OF SAB)

Global expert on use of psychedelics for medical indications



Imperial College
London



DANIEL CLAUW, M.D.

World –renowned expert on fibromyalgia and nociplastic pain




RACHEL WEVRICK, PH.D.

Leading researcher in genetic development, including eating disorders



JOEL CASTELLANOS, M.D.

Leading chronic pain researcher and physician



WILLIAM SCHMIDT, PH.D.

Expert in drug development for Pain indications



DEREK OTT, M.D.

30+ years of experience in the pharmaceutical industry including manufacturing and drug delivery



Psilocybin & MDMA recognised as “Medicines” by TGA

Landmark TGA Decision Makes Australia the First Country Globally to Officially Recognise Psychedelics as Legitimate Medicines

- Medical use of psilocybin and MDMA rescheduled from Schedule 9 (prohibited substances) to Schedule 8 (controlled medicines)*
- Authorised psychiatrists now able to prescribe psilocybin for treatment resistant depression and MDMA for treatment resistant post-traumatic stress disorder**

*Subject to full documentation of treatment protocols, approval by a HREC and the psychiatrist receiving AP designation from the TGA. When these parameters are met, psilocybin will be reclassified from Schedule 9 to Schedule 8 (Controlled Substances). The substances will retain their Schedule 9 classification in all other circumstances including for clinical trials. Psilocin is currently listed in Schedule 9 of the Poisons Standard, meaning that it is a “prohibited substance”, which is defined as a substance which may be abused and misused, the manufacture, possession, sale and use of which is prohibited by law, except when required for medical or scientific research, or for analytical, teaching or training purposes, with the approval of Commonwealth and/or State or Territory health authorities.

** Tryp is not currently trialing psilocybin to treat treatment resistant depression and does not currently have a drug candidate that is eligible to be treated as a Schedule 8 product.



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists


Published: 3 February 2023

From 1 July this year, medicines containing the psychedelic substances psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) can be prescribed by specifically authorised psychiatrists for the treatment of certain mental health conditions.

The Therapeutic Goods Administration (TGA) will permit the prescribing of MDMA for the treatment of post-traumatic stress disorder and psilocybin for treatment-resistant depression. These are the only conditions where there is currently sufficient evidence for potential benefits in certain patients.

Psychedelics now recognised by regulatory bodies

- MDMA & Psilocybin now recognised as “Medicines” in Australia
 - Prescribing enabled by authorized psychiatrists
- Psychedelics represent a multi-billion \$ sector
- Over 100 universities worldwide performing psychedelic research
- US government agencies (NIH) now funding psychedelic research
- Acknowledgement by regulatory bodies that psychedelics have a path towards approval



reMIND February 2024



The Wall Street Journal Aug 2022



Sydney Morning Herald Feb 2023

IV-infused Psilocin: A Precision Approach to Psychedelics

	IV-infused Psilocin	Oral Psilocybin *
Short treatment duration of 1-2 hours	✓	✗ -8-10 hours
Quick onset of psychedelic state (approx. 15 minutes)	✓	✗ 1-2 hours
Precision targeting of drug blood levels in patients	✓	✗ highly variable
Quickly reversible in emergency	✓	✗
Strong IP positioning	✓	✗
Commercially scalable	✓	?

* Companies developing oral psilocybin include: Compass Pathways, USONA

IV-Infused Psilocin: Precision Psychedelics

Delivering psilocin directly into the blood stream allows patients to experience the therapeutic benefits of psilocybin/psilocin in a more precise, controlled and shorter duration environment

“By allowing rapid initiation and termination of the psychedelic experience, as well as providing highly refined control over the depth and duration of that experience, I believe TRP-8803 has a very strong potential to shift the treatment paradigm for fibromyalgia and binge eating disorder, as well as certain types of depression, pain and obsessive-compulsive disorders.”

Robin Carhart-Harris, Ph.D. - Chairman, Advisory Board


Investor presentation – May 2024



IV-infused Psilocin: overcomes the limitations of oral psilocybin

Limitations of orally administered psilocybin:

- **High patient variability** in terms of drug blood levels (refer graphic)
 - Psilocybin is converted into psilocin, the psychoactive metabolite, in the body
 - Percent conversion varies for each patient:
 - Effectiveness of enzymes responsible for conversion is specific to each patient
 - First pass metabolism through liver contributes to variable blood levels of psilocin
 - May negatively impact efficacy and safety
- **Long duration of treatment** of approx. 8-10 hours
 - Induction phase into psychedelic state can be 1-2 hours
 - Psychedelic state can persist for an additional 6-8 hours
 - Therapists needed with patient throughout treatment period
 - Poor economics makes commercial scale-up challenging
- **Patient acceptance**
- **Intellectual Property**



Trial Pipeline

 Current
 Next 12-18 months**

TRP-8803	INDICATION	PHASE 1*	PHASE 2	
Proprietary IV-infused synthetic psilocin	BINGE EATING DISORDER			
	FIBROMYALGIA			
	IRRITABLE BOWEL SYNDROME			
TRP-8802	INDICATION	IND CLEARED	PHASE 2 a	PARTNER
Oral, synthetic psilocybin sourced from Usona Institute	BINGE EATING DISORDER			
	FIBROMYALGIA			
	IRRITABLE BOWEL SYNDROME			

*Healthy volunteer dose ranging study in H1 2024 will support IND submissions for Phase 2a studies in patients

**The timetable is indicative only and is subject to change.

TRP-8803: Healthy Human Volunteer Study (Australia)

IV-Infused Psilocin

- Precision targeting of drug blood levels
- Fast onset time to psychedelic state (approx. 15 minutes)
- Short duration of treatment (1-2 hours)
- Reversible in emergency
- IP protection
- Commercially scalable
- Enables clinical studies in multiple indications

HREC approved Trial expected to be completed in H2 2024

PRODUCT	NO. OF PATIENTS	COLLABORATOR	DESIGN	DATA READ OUT	NEXT STEPS
TRP-8803	9	iNGENu, C-Max	Open label with therapist support	H2 2024	First patient treatment (H1 2024)

Pilot Studies Using Oral Psilocybin

- A cost effective method for identifying safety and efficacy signals for new indications
- Access to a common and readily available generic molecule for clinical trials now
- Earliest possible enhancement of IP portfolio
- Ability to Optimise clinical trial protocols
- Establishes collaborations with key Universities
- Provides significant clinical risk reduction while allowing for acceleration of proprietary drug development

TRP-8802 - ORAL PSILOCYBIN

Pilot studies to identify
positive signal in new
indications

Partnered with leading
academic institutions



TRP-8803 - IV PSILOCIN

Pathway for Phase 2b
trials and beyond

Commercially scalable
platform

Binge Eating Disorder: Phase 2a clinical trial



BINGE EATING DISORDER (BED)

Recurring episodes of eating large quantities of food and feeling unable to stop

Approximately 30% of people seeking weight loss treatments show signs of BED

No currently approved treatments developed specifically for BED

"We are very excited for the potential of TRYP's treatment. The potential impact on patients' lives is that it would be life changing for them."

Jennifer Miller, MD, Professor, University of Florida, Principal Investigator

"These results from a single dose of psilocybin combined with therapy are clinically meaningful and highly promising. The magnitude of changes for most participants in binge eating, anxiety, and depression are dramatic.."

Jessie Dallery, Ph.D. Professor, University of Florida, Lead Psychologist


PRODUCT	NO. OF PATIENTS	COLLABORATOR	DESIGN	DATA READ OUT	NEXT STEPS
TRP-8802	6	UNIVERSITY OF FLORIDA	Open label with psychotherapy	Data announced Q1 2023	Scientific paper publication

**Positive interim data announced in January 2023, including mean reduction >80% for Binge Eating Score
Confirmed as viable target for future studies using TRP-8803**


University of Florida Phase 2a Interim Analysis:

Significant reduction in frequency & extent of binge eating (daily, 4 weeks)

Question 1: Over the past 24 hours, how many times have you eaten what other people would regard as an unusually large amount of food (given the circumstances)?



Question 2: On how many of these times did you have a sense of having lost control over your eating (at the time that you were eating)?




University of Florida Phase 2a Interim Analysis:

Durable effect on binge eating episodes


Question 3:

Over the past 28 days, on how many DAYS have such episodes of overeating occurred (i.e. you have eaten an unusually large amount of food and have had a sense of loss of control at the time)?




University of Florida Phase 2a Interim Analysis:

Significant fall in Hospital Anxiety & Depression Scores (HADS)



HADS Anxiety Score



HADS Depression Score

Fibromyalgia: Phase 2a clinical trial

FIBROMYALGIA

Chronic condition causing widespread pain and fatigue

Many cases linked to adverse physical or emotional events

Limited success with currently approved drugs

Co-morbidities include depression and health-related anxiety, sleep disturbances

“Existing treatment options for fibromyalgia are often ineffective and show significant side effects. We are excited to be working with the team at Trypt Therapeutics, who have shown exceptional scientific rigor in their approach to evaluate a new treatment paradigm for the millions of patients suffering from fibromyalgia and other pain-related indications”

Daniel Clauw, MD, Professor, University of Michigan

PRODUCT	NO. OF PATIENTS	COLLABORATOR	DESIGN	DATA READ OUT	NEXT STEPS
TRP-8802	Up to 10	 UNIVERSITY OF MICHIGAN	Open label with psychotherapy	Initial data expected in H2 2024	Completion of trial

First patient dosed in December 2023
Enrollment of all patients ongoing

Irritable Bowl Syndrome: Phase 2a clinical trial

IBS

Chronic abdominal pain + altered bowel habits

Affects 10-15% worldwide (~790M people)*; leading cause of work absenteeism;**

Associated with fibromyalgia, chronic fatigue, depression, anxiety

More common in those with early life adversity/trauma

Pathophysiology: visceral hypersensitivity

90% of serotonin synthesized in gut; enteric nervous system***

“There is tremendous potential for the treatment of debilitating IBS and other disorders of gut-brain interaction by utilizing the combined administration of psilocybin and psychotherapy. Our clinical study will examine how psilocybin-assisted psychotherapy may alter important brain networks involved in chronic pain and gastrointestinal-specific anxiety in IBS to bolster the neural flexibility in these patients and thereby reduce visceral hypersensitivity”

Erin Mauney, MD, Massachusetts General Hospital

PRODUCT	NO. OF PATIENTS	COLLABORATOR	DESIGN	DATA READ OUT	NEXT STEPS
TRP-8802	Up to 10	 MASSACHUSETTS GENERAL HOSPITAL	Open label with psychotherapy	H2 2024	First patient enrolment

IND Letter to Proceed received from FDA, and IRB approval granted

Next steps: First patient enrolment

* <https://gi.org/topics/irritable-bowel-syndrome>

** <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010380/>

*** <https://www.nature.com/articles/s41598-022-05756-0>

Robust Intellectual Property Portfolio

Patent applications and trade secrets based on novel methods for manufacturing, formulation, dosing, and specific disease indications

- Filed a provisional patent in March 2021 (US 63/161,070) covering TRP-8803 (**IV-infused Psilocin**); converted to PCT filing March 2022; published September 22, 2022
- Provisional patent application covering the use of psilocybin in the treatment of Binge Eating Disorder (BED) filed June 2022
- Provisional patent application for the treatment of fibromyalgia submitted September 2022
- Provisional patent application for salt & co-formers of TRP-8803 filed September 2022
- Provisional patent for IBS filed January 2, 2023

MORRISON
FOERSTER

Allens > < Linklaters

Multiple Near-Term Milestones and Catalysts*

Catalyst	Timeframe	Status
Completion of Tryp Therapeutics Inc. acquisition	H1 2024	✓
\$6.5m capital raise	H1 2024	✓
Recommencement of trading on ASX	H1 2024	✓
Appointments to strengthen Scientific Advisory Board	H1 2024	
Start of TRP-8803 Phase 1 trial (Australia)	H1 2024	
TRP-8802 Fibromyalgia Phase 2a patient enrolment (in collaboration with University of Michigan)	H1 2024	
TRP-8802 Irritable Bowel Syndrome (IBS) Phase 2a trial commencement (alongside Harvard University)	H2 2024	
Completion of TRP-8803 Phase 1 trial (Australia) and interim results	H2 2024	
TRP-8802 Fibromyalgia Phase 2a interim data	H1 2025	
TRP-8802 IBS Phase 2a interim data	H1 2025	
TRP-8802 Fibromyalgia Phase 2a final data	H1 2025	
TRP-8803 Phase 2 trial authorisations	H1 2025	
TRP-8803 Phase 2 trial eating disorder trial commencement (Australia)	H1 2025	
TRP-8802 IBS Phase 2a final data	H2 2025	
Commencement of TRP-8803 Phase 2 chronic pain trial (Australia)	H2 2025	

*The timetable is indicative only and is subject to change (Calendar year is used)

Psychedelic Market Landscape

Company	Ticker	Mkt cap (AUD)	Compound	Stage	Indication(s)
AbbVie Inc.	NYSE: ABBV	414Bn	Multiple	Phase 1 / 2 completed	Multiple
Compass Pathways	NASDAQ: CMPS	\$912m	Psilocybin	Phase 3	Treatment resistant depression, PTSD, Anorexia
GH Research	NASDAQ: CMPS	469.7m	5-MeO-DMT	Phase 1/2 completed	Treatment resistant depression
Atai Life Sciences	NASDAQ: ATAI	458m	Psilocybin	Preclinical - Phase 2	Depression, Anxiety, Schizophrenia, Opioid Use Disorder, PTSD
Cybin	NYSE: CYBN	227.2m	Psilocybin, DMT	Preclinical - Phase 2	Depression, Anxiety, Alcohol Use Disorder, Neuroinflammation
MindMed/Lykos	NASDAQ: MNMD	154.7m	LSD, MDMA	Phase 2	Anxiety, ADHD
Icannex Healthare	ASX: IHL / NASDAQ: IXHL	\$102.6m	Psilocybin & CBD	Phase 1 completed	Anxiety
Little Green Pharma	ASX: LGP	42m	Psilocybin & CBD	Preclinical	Treatment resistant depression
Emyria	ASX: EMD	24.5m	MDMA & CBD	Preclinical	Parkinson's, Fibrotic Disease, pain
Tryptamine Therapeutics	ASX: TYP	22.7m	Psilocin & psilocybin	Phase 2	Eating disorders, Chronic pain (nociplastic)

Market data at 22 January 2024
*USD/AUD exchange rate of 1.52

Investment highlights

A Precision Approach to Psychedelic Medicine

- **IV-Infused Psilocin** overcomes critical challenges of oral psilocybin dosing, providing significant competitive advantages
- Transformative and commercially scalable intellectual property (IV-Infused Psilocin)
- Potential beneficiary of recent positive changes to TGA regulation in Australia
- Multiple near-term value-creating catalysts
- First mover advantage and IP protection for each indication being targeted
- Clinical trials ongoing, with positive efficacy data already announced
- Partnered with multiple leading academic institutions for Phase 2 trials
- 43.5% R&D credit for qualifying clinical trials in Australia
- Experienced management team with proven biotech and drug approval success
- World-class Scientific Advisory Board



Contact

Jason Carroll
Chief Executive Officer
jcarroll@trypttherapeutics.com

Peter Molloy
Chief Business Officer
pmolloy@trypttherapeutics.com

Website:
www.trypttherapeutics.com

Socials:
X (Twitter) [@trypttherapeutic](https://twitter.com/trypttherapeutic)

